Literature DB >> 11673578

Daytime sleepiness and other sleep disorders in Parkinson's disease.

W G Ondo1, K Dat Vuong, H Khan, F Atassi, C Kwak, J Jankovic.   

Abstract

BACKGROUND: PD is associated with a variety of sleep problems. The dopamine agonists (DA) pramipexole and ropinirole were recently implicated in causing "sleep attacks" and motor vehicle accidents.
METHODS: In order to determine the overall rate of subjective sleep problems in PD and to determine if any factors, including specific medications, correlate with sleep pathology, the authors surveyed consecutive patients with PD seen over a 3-month period in a Movement Disorders Clinic. The authors collected demographic and medication data, and the patients completed the Epworth Sleepiness Scale (ESS), questions assessing the presence of restless legs syndrome (RLS), a modified National Sleep Foundation sleep survey, and specific questions regarding falling asleep while driving.
RESULTS: A total of 320 patients completed the questionnaire. The authors eliminated 17, six for incomplete data and 11 for having a primary diagnosis other than PD. The mean age of the remaining 303 patients was 67.1 +/- 10.7 years, and the mean duration of PD was 9.1 +/- 5.7 years. The ESS scores averaged 11.1 +/- 5.9, and in 50.2% of patients the score was abnormally high (>10). Stepwise regression analysis found that sleepiness correlated with longer duration of PD (p < 0.001), more advanced PD (p < 0.004), male sex (p < 0.001), and the use of any DA (p < 0.003). The soporific effects of the three most common DA (pramipexole, ropinirole, and pergolide) were similar. Falling asleep while driving was reported by 63/279 (22.6%) of current drivers and correlated with higher ESS scores (p < 0.05). Other sleep disorders, including RLS, were also frequently reported.
CONCLUSION: Daytime sleepiness is common in PD and correlates with more advanced and longer duration of PD, and male sex. The DA were also independently associated with daytime sleepiness, but in this group, no single DA was more culpable than the others.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673578     DOI: 10.1212/wnl.57.8.1392

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  71 in total

1.  The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease.

Authors:  K R Chaudhuri; S Pal; A DiMarco; C Whately-Smith; K Bridgman; R Mathew; F R Pezzela; A Forbes; B Högl; C Trenkwalder
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  Sleep disturbances in untreated Parkinson's disease.

Authors:  Jitka Bušková; Jiří Klempíř; Veronika Majerová; Jana Picmausová; Karel Sonka; Robert Jech; Jan Roth; Evžen Růžička
Journal:  J Neurol       Date:  2011-06-03       Impact factor: 4.849

3.  Development of the National Healthy Sleep Awareness Project Sleep Health Surveillance Questions.

Authors:  Timothy I Morgenthaler; Janet B Croft; Leslie C Dort; Lauren D Loeding; Janet M Mullington; Sherene M Thomas
Journal:  J Clin Sleep Med       Date:  2015-09-15       Impact factor: 4.062

4.  Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?

Authors:  Christian Baumann; Luigi Ferini-Strambi; Daniel Waldvogel; Esther Werth; Claudio Lino Bassetti
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

5.  Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.

Authors:  W G Ondo; R Fayle; F Atassi; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

6.  Nature and variants of idiopathic restless legs syndrome: observations from 152 patients referred to secondary care in the UK.

Authors:  R Holmes; S Tluk; V Metta; P Patel; R Rao; A Williams; K R Chaudhuri
Journal:  J Neural Transm (Vienna)       Date:  2007-01-22       Impact factor: 3.575

7.  Evaluating daytime alertness in individuals with Restless Legs Syndrome (RLS) compared to sleep restricted controls.

Authors:  Charlene Gamaldo; Amy R Benbrook; Richard P Allen; Oluwamurewa Oguntimein; Christopher J Earley
Journal:  Sleep Med       Date:  2008-01-28       Impact factor: 3.492

8.  Visual and cognitive predictors of driving safety in Parkinson's disease patients.

Authors:  M M Amick; J Grace; B R Ott
Journal:  Arch Clin Neuropsychol       Date:  2007-09-11       Impact factor: 2.813

9.  Modafinil for Parkinson's disease fatigue.

Authors:  Hilary L Tyne; Joanne Taylor; Gus A Baker; Malcolm J Steiger
Journal:  J Neurol       Date:  2009-10-20       Impact factor: 4.849

Review 10.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.